Literature DB >> 27593589

Induction of rapid, reproducible hepatic ablations using next-generation, high frequency irreversible electroporation (H-FIRE) in vivo.

Imran A Siddiqui1, Eduardo L Latouche2, Matthew R DeWitt2, Jacob H Swet1, Russell C Kirks1, Erin H Baker1, David A Iannitti1, Dionisios Vrochides1, Rafael V Davalos2, Iain H McKillop3.   

Abstract

INTRODUCTION: Irreversible electroporation (IRE) offers an alternative to thermal tissue ablation in situ. High-frequency IRE (H-FIRE), employing ultra-short bipolar electrical pulses, may overcome limitations associated with existing IRE technology to create rapid, reproducible liver ablations in vivo.
METHODS: IRE electrodes (1.5 cm spacing) were inserted into the hepatic parenchyma of swine (n = 3) under surgical anesthesia. In the absence of paralytics or cardiac synchronization five independent H-FIRE ablations were performed per liver using 100, 200, or 300 pulses (2250 V, 2-5-2 μs configuration). Animals were maintained under isoflurane anesthesia for 6 h prior to analysis of ablation size, reproducibility, and apoptotic cell death.
RESULTS: Mean ablation time was 230 ± 31 s and no EKG abnormalities occurred during H-FIRE. In 1/15 HFIRE's minor muscle twitch (rectus abdominis) was recorded. Necropsy revealed reproducible ablation areas (34 ± 4 mm(2), 88 ± 11 mm(2) and 110 ± 11 mm(2); 100-, 200- and 300-pulses respectively). Tissue damage was predominantly apoptotic at pulse delivery ≤200 pulses, after which increasing evidence of tissue necrosis was observed.
CONCLUSION: H-FIRE can be used to induce rapid, predictable ablations in hepatic tissue without the need for intraoperative paralytics or cardiac synchronization. These advantages may overcome limitations that restrict currently available IRE technology for hepatic ablations.
Copyright © 2016 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27593589      PMCID: PMC5011100          DOI: 10.1016/j.hpb.2016.06.015

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  32 in total

1.  Theoretical considerations of tissue electroporation with high-frequency bipolar pulses.

Authors:  Christopher B Arena; Michael B Sano; Marissa Nichole Rylander; Rafael V Davalos
Journal:  IEEE Trans Biomed Eng       Date:  2010-12-23       Impact factor: 4.538

2.  Outcomes of surgical resection and loco-regional therapy in patients with stage 3A hepatocellular carcinoma: a retrospective review from the national cancer database.

Authors:  Ramanathan M Seshadri; Erin H Baker; Megan Templin; Ryan Z Swan; John B Martinie; Dionisios Vrochides; David A Iannitti
Journal:  HPB (Oxford)       Date:  2015-08-14       Impact factor: 3.647

Review 3.  Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review.

Authors:  Yun Ku Cho; Hyunchul Rhim; Sangik Noh
Journal:  J Gastroenterol Hepatol       Date:  2011-09       Impact factor: 4.029

4.  Colour doppler ultrasonography provides real-time microwave field visualisation in an ex vivo porcine model.

Authors:  Jim F Byrd; Neal Agee; Iain H McKillop; David Sindram; John B Martinie; David A Iannitti
Journal:  HPB (Oxford)       Date:  2011-03-29       Impact factor: 3.647

5.  Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model.

Authors:  Dominik Vollherbst; Robert C Bertheau; Stefan Fritz; Carolin Mogler; Hans-Ulrich Kauczor; Eduard Ryschich; Boris A Radeleff; Philippe L Pereira; Christof M Sommer
Journal:  J Vasc Interv Radiol       Date:  2016-04-18       Impact factor: 3.464

6.  International multicentre prospective study on microwave ablation of liver tumours: preliminary results.

Authors:  David M Lloyd; Kwan N Lau; Fenella Welsh; Kit-Fai Lee; David J Sherlock; Michael A Choti; John B Martinie; David A Iannitti
Journal:  HPB (Oxford)       Date:  2011-06-24       Impact factor: 3.647

7.  Microwave ablation using 915-MHz and 2.45-GHz systems: what are the differences?

Authors:  Kerri A Simo; Victor B Tsirline; David Sindram; Matthew T McMillan; Kyle J Thompson; Ryan Z Swan; Iain H McKillop; John B Martinie; David A Iannitti
Journal:  HPB (Oxford)       Date:  2013-03-14       Impact factor: 3.647

8.  Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes.

Authors:  Ryan Z Swan; David Sindram; John B Martinie; David A Iannitti
Journal:  J Gastrointest Surg       Date:  2013-02-13       Impact factor: 3.452

9.  The role of pH fronts in reversible electroporation.

Authors:  Pablo Turjanski; Nahuel Olaiz; Felipe Maglietti; Sebastian Michinski; Cecilia Suárez; Fernando Victor Molina; Guillermo Marshall
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by "electric field sinks".

Authors:  Alexander Golberg; Bote G Bruinsma; Basak E Uygun; Martin L Yarmush
Journal:  Sci Rep       Date:  2015-02-16       Impact factor: 4.379

View more
  16 in total

1.  Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.

Authors:  Haifeng Wang; Wei Xue; Weigang Yan; Lei Yin; Baijun Dong; Biming He; Yongwei Yu; Wentao Shi; Zhien Zhou; Hengzhi Lin; Yi Zhou; Yanqing Wang; Zhenkai Shi; Shancheng Ren; Xu Gao; Linhui Wang; Chuanliang Xu
Journal:  JAMA Surg       Date:  2022-08-01       Impact factor: 16.681

Review 2.  Novel ablation methods for treatment of gliomas.

Authors:  Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus
Journal:  J Neurosci Methods       Date:  2020-02-14       Impact factor: 2.390

Review 3.  Gene transfer to plants by electroporation: methods and applications.

Authors:  Ibrahim Ilker Ozyigit
Journal:  Mol Biol Rep       Date:  2020-04-02       Impact factor: 2.316

4.  Avoiding nerve stimulation in irreversible electroporation: a numerical modeling study.

Authors:  Borja Mercadal; Christopher B Arena; Rafael V Davalos; Antoni Ivorra
Journal:  Phys Med Biol       Date:  2017-10-04       Impact factor: 3.609

5.  High-Frequency Irreversible Electroporation for Treatment of Primary Liver Cancer: A Proof-of-Principle Study in Canine Hepatocellular Carcinoma.

Authors:  Brittanie R Partridge; Timothy J O'Brien; Melvin F Lorenzo; Sheryl L Coutermarsh-Ott; Sabrina L Barry; Krystina Stadler; Noelle Muro; Mitchell Meyerhoeffer; Irving C Allen; Rafael V Davalos; Nikolaos G Dervisis
Journal:  J Vasc Interv Radiol       Date:  2020-01-16       Impact factor: 3.464

6.  The use of high-frequency short bipolar pulses in cisplatin electrochemotherapy in vitro.

Authors:  Maria Scuderi; Matej Rebersek; Damijan Miklavcic; Janja Dermol-Cerne
Journal:  Radiol Oncol       Date:  2019-06-01       Impact factor: 2.991

7.  Single exponential decay waveform; a synergistic combination of electroporation and electrolysis (E2) for tissue ablation.

Authors:  Nina Klein; Enric Guenther; Paul Mikus; Michael K Stehling; Boris Rubinsky
Journal:  PeerJ       Date:  2017-04-18       Impact factor: 2.984

8.  First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer.

Authors:  Shoulong Dong; Haifeng Wang; Yajun Zhao; Yinghao Sun; Chenguo Yao
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 9.  Recent progress in pulsed electric field ablation for liver cancer.

Authors:  Zhen-Guo Liu; Xin-Hua Chen; Zu-Jiang Yu; Jun Lv; Zhi-Gang Ren
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

10.  Nanosecond range electric pulse application as a non-viral gene delivery method: proof of concept.

Authors:  Paulius Ruzgys; Vitalij Novickij; Jurij Novickij; Saulius Šatkauskas
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.